Immunological changes and prevention of disease progression through elotuzumab therapy in refractory IgG4-related sclerosing mesenteritis.

Autor: Comdühr, Sara, Dübbers, Alexander, Tharun, Lars, Graßhoff, Hanna, Stone, John, Pitann, Silke, Riemekasten, Gabriela, Lamprecht, Peter
Předmět:
Zdroj: Rheumatology; Nov2022, Vol. 61 Issue 11, pe334-e336, 3p
Abstrakt: The article presents a case report of a 67-year-old Caucasian female with abdominal pain due to biopsy-proven IgG4-RSM and the application of elotuzumab therapy. The patient's disease has remained stable for 9 months which suggests a therapeutic elotuzumab-induced effect with prevention of disease progression and an immunological response. Elotuzumab could be a therapeutic option in IgG4-related disease (IgG4-RD) and is being tested as of 2022.
Databáze: Complementary Index